aap Implantate sold its biomaterials unit to an undisclosed private equity firm in the EU for €36MM (~US $40.3MM). For 2015, the unit achieved revenue of ~US $17.9MM. Upon closing, which is slated for 2Q16, aap will proceed as a pure-play trauma entity.
aap’s trauma products include a standard osteosynthesis portfolio and LOQTEQ® anatomical locking compression technology. LOQTEQ launched internationally in 2011, and the company received its first FDA 510(k) clearance for a LOQTEQ small fragment plating system in 3Q12. aap also holds IP for a multifunctional antibacterial silver implant coating.
The divested Biomaterials unit is specialized in development, production and marketing of bone substitutes, collagen fleece, cements, mixing systems and related accessories.
Last year at this time, aap Implantate announced that advanced-stage negotiations for sale of this subsidiary were ceased, as final transaction terms and conditions could not be met.
Update 5/11/16: The buyer is Keensight Capital.
aap Implantate sold its biomaterials unit to an undisclosed private equity firm in the EU for €36MM (~US $40.3MM). For 2015, the unit achieved revenue of ~US $17.9MM. Upon closing, which is slated for 2Q16, aap will proceed as a pure-play trauma entity.
aap Implantate sold its biomaterials unit to an undisclosed private equity firm in the EU for €36MM (~US $40.3MM). For 2015, the unit achieved revenue of ~US $17.9MM. Upon closing, which is slated for 2Q16, aap will proceed as a pure-play trauma entity.
aap’s trauma products include a standard osteosynthesis portfolio and LOQTEQ® anatomical locking compression technology. LOQTEQ launched internationally in 2011, and the company received its first FDA 510(k) clearance for a LOQTEQ small fragment plating system in 3Q12. aap also holds IP for a multifunctional antibacterial silver implant coating.
The divested Biomaterials unit is specialized in development, production and marketing of bone substitutes, collagen fleece, cements, mixing systems and related accessories.
Last year at this time, aap Implantate announced that advanced-stage negotiations for sale of this subsidiary were ceased, as final transaction terms and conditions could not be met.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
